Hypertriglyceridemia. Aspects of epidemiology and etiopathogenesis

• Andrey G. Obrezan
• Elena K. Serezhina
• Alexander V. Shomin

Abstract

Hypertriglyceridemia is a lipid metabolism disorder associated with an increased risk of cardiovascular diseases. This literature review illustrates current data regarding the epidemiological and etiopathogenetic aspects of this pathology, which allow us to understand the structure of this disease more deeply.

Keywords:hypertriglyceridemia; dyslipidemia; triglycerides; lipids; lipidology; cholesterol; atherosclerosis; cardiovascular diseases

References

1. De Pretis N., Amodio A., Frulloni L. Hypertriglyceridemic pancreatitis: epidemiology, pathophysiology and clinical management. United European Gastroenterol J. 2018; 6 (5): 649–55. DOI: https://doi.org/10.1177/2050640618755002
2. Generoso G., Janovsky C.C.P.S., Bittencourt M.S. Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis. Curr Opin Endocrinol Diabetes Obes. 2019; 26 (2): 109–16. DOI: https://doi.org/10.1097/MED.0000000000000468
3. Nordestgaard L.T., Christoffersen M., Afzal S., et al. Triglycerides as a shared risk factor between dementia and atherosclerotic cardiovascular disease: a study of 125 727 individuals. Clin Chem. 2021; 67 (1): 245–55. DOI: https://doi.org/10.1093/clinchem/hvaa269
4. Toth P.P., Fazio S., Wong N.D., et al. Risk of cardiovascular events in patients with hypertriglyceridaemia: a review of real-world evidence. Diabetes Obes Metab. 2020; 22 (3): 279–89. DOI: https://doi.org/10.1111/dom.13921
5. Hoogeveen R.C., Ballantyne C.M. Residual cardiovascular risk at low LDL: remnants, lipoprotein (a), and inflammation. Clin Chem. 2021; 67 (1): 143–53.
6. Hori M., Ohta N., Takahashi A., Masuda H., Isoda R., Yamamoto S., et al. Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients. Atherosclerosis. 2019; 289: 101–8. DOI: https://doi.org/10.1016/j.atherosclerosis.2019.08.004
7. Zhang B.H., Yin F., Qiao Y.N., et al. Triglyceride and triglyceride-rich lipoproteins in atherosclerosis. Front Mol Biosci. 2022; 9: 909151. DOI: https://doi.org/10.3389/fmolb.2022.909151
8. Si S., Hou L., Chen X., et al. Exploring the causal roles of circulating remnant lipid profile on cardiovascular and cerebrovascular diseases: Mendelian randomization study. J Epidemiol. 2022; 32 (5): 205–14. DOI: https://doi.org/10.2188/jea.JE-20200305
9. De Carvalho C.C.C.R., Caramujo M.J. The various roles of fatty acids. Molecules. 2018; 23 (10): 2583. DOI: https://doi.org/10.3390/molecules23102583
10. Hegele R.A. Apolipoprotein C-II: a new look at an old protein. Eur Heart J. 2023; 44 (25): 2345–7. DOI: https://doi.org/10.1093/eurheartj/ehad237
11. Ginsberg H.N., Packard C.J., Chapman M.J., et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021; 42 (47): 4791–806. DOI: https://doi.org/10.1093/eurheartj/ehab551
12. Metelskaya V.A. Multimarker diagnostic panels for atherosclerosis. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2018; 23 (8): 65–72. (in Russian)
13. Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019; 73 (24): 3168–209. DOI: https://doi.org/10.1016/j.jacc.2018.11.002
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002; 106; 3143–421.
15. Visseren F.L.J., Mach F., Smulders Y.M., et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42 (34): 3227–337. DOI: https://doi.org/10.1093/eurheartj/ehab484
16. НеgеlеА., Ginsberg Н.N., Chapman М.J., еt аl. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol. 2014; 2 (8): 655–66. DOI: https://doi.org/10.1016/S2213-8587(13)70191-8
17. Kiss L., Für G., Mátrai P., Hegyi P., Ivány E. The effect of serum triglyceride concentration on the outcome of acute pancreatitis: systematic review and meta-analysis. Sci Rep. 2018; 8 (1): 14096. DOI: https://doi.org/10.1038/s41598-018-32337-x
18. Guo Y.Y., Li H.X., Zhang Y., He W.H. Hypertriglyceridemia-induced acute pancreatitis: progress on disease mechanisms and treatment modalities. Discov Med. 2019; 27 (147): 101–9.
19. Zhang X., Sessa W.C., Fernández-Hernando C. Endothelial transcytosis of lipoproteins in atherosclerosis. Front Cardiovasc Med. 2018; 5: 130. DOI: https://doi.org/10.3389/fcvm.2018.00130
20. Su X., Kong Y., Peng D.Q. New insights into apolipoprotein A5 in controlling lipoprotein metabolism in obesity and the metabolic syndrome patients. Lipids Health Dis. 2018; 17: 174. DOI: https://doi.org/10.1186/s12944-018-0833-2
21. Cruz-Bautista I. Approach to hypertriglyceridemia syndromes: the importance of distinguishing between primary and secondary etiologies. Cardiovasc Metab Sci. 2021; 32 (suppl 3): s236–41. DOI: https://doi.org/10.35366/100804
22. Dib I., Khalil A., Chouaib R., et al. Apolipoprotein C-III and cardiovascular diseases: when genetics meet molecular pathologies. Mol Biol Rep. 2021; 48: 875–86. DOI: https://doi.org/10.1007/s11033-020-06071-5
23. Kukharchuk V.V., Ezhov M.V., Sergienko I.V., Arabidze G.G., Balakhonova T.V., Gurevich V.S., et al. Eurasian Association of Cardiology (EAC)/Russian National Atherosclerosis Society (RNAS, Russia) guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2020). Eurasian heart journal. 2020; (2): 6–29. DOI: https://doi.org/10.38109/2225-1685-2020-2-6-29 (in Russian)
24. Jannat Ali Pour N., Zabihi-Mahmoudabadi H., Ebrahimi R., et al. Principal component analysis of adipose tissue gene expression of lipogenic and adipogenic factors in obesity. BMC Endocr Disord. 2023; 23: 94. DOI: https://doi.org/10.1186/s12902-023-01347-w
25. Laufs U., Parhofer K.G., Ginsberg H.N., Hegele R.A. Clinical review on triglycerides. Eur Heart J. 2020; 41: 99–109.
26. Vekic J., Zeljkovic A., Stefanovic A., Jelic-Ivanovic Z., Spasojevic-Kalimanovska V. Obesity and dyslipidemia. Metabolism. 2019; 92: 71–81. DOI: https://doi.org/10.1016/j.metabol.2018.11.005
27. Fahed G., Aoun L., Bou Zerdan M., Allam S., Bou Zerdan M., Bouferraa Y., et al. Metabolic syndrome: updates on pathophysiology and management in 2021. Int J Mol Sci. 2022; 23: 786. DOI: https://doi.org/10.3390/ijms23020786
28. Parhofer K.G., Laufs U. The diagnosis and treatment of hypertriglyceridemia. Dtsch Arztebl Int. 2019; 116 (49): 825–32.
29. Kurti S.P., Wisseman B.L., Akers J.D., Edwards E.S. Saturated fatty acids consumed in smoothies increase glucose and metabolic load index in young adults compared to polyunsaturated omega-3-fatty acids. Nutrients. 2023; 15: 642. DOI: https://doi.org/10.3390/nu15030642
30. Mach F., Baigent C, Catapano A.L., et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41 (1): 111–88. DOI: https://doi.org/10.1093/eurheartj/ehz455
31. Pouwels S., Sakran N., Graham Y., et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022; 22: 63. DOI: https://doi.org/10.1186/s12902-022-00980-1
32. Hartz J.C., de Ferranti S., Gidding S. Hypertriglyceridemia in diabetes mellitus: implications for pediatric care. J Endocr Soc. 2018; 2 (6): 497–512. DOI: https://doi.org/10.1210/js.2018-00079
33. Schaefer E.J., Geller A.S., Endress G. The biochemical and genetic diagnosis of lipid disorders. Curr Opin Lipidol. 2019; 30 (2): 56–62.
34. Sadeghi H.M., Adeli I., Calina D., Docea A.O., Mousavi T., Daniali M., et al. Polycystic ovary syndrome: a comprehensive review of pathogenesis, management, and drug repurposing. Int J Mol Sci. 2022; 23: 583. DOI: https://doi.org/10.3390/ijms23020583
35. Dalle H., Garcia M., Antoine B., Boehm V., Huong Do T.T., Buyse M., et al. Adipocyte glucocorticoid receptor deficiency promotes adipose tissue expandability and improves the metabolic profile under corticosterone exposure. Diabetes. 2019; 68 (2): 305–17. DOI: https://doi.org/10.2337/db17-1577
36. Xu C., He J., Jiang H., et al. Direct effect of glucocorticoids on lipolysis in adipocytes. Mol Endocrinol. 2009; 23 (8): 1161–70. DOI: https://doi.org/10.1210/me.2008-0464
37. Grundy S.M., Stone N.J., Bailey A.L., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. 2019; 139: e1082–143.
38. Duntas L.H., Brenta G. A renewed focus on the association between thyroid hormones and lipid metabolism. Front Endocrinol. 2018; 9: 511. DOI: https://doi.org/10.3389/fendo.2018.00511
39. Kersten S. ANGPTL3 as therapeutic target. Curr Opin Lipidol. 2021; 32 (6): 335–41. DOI: https://doi.org/10.1097/MOL.0000000000000789
40. Nasioudis D., Doulaveris G., Kanninen T.T. Dyslipidemia in pregnancy and maternal-fetal outcome. Minerva Ginecol. 2019; 71 (2): 155–62. DOI: https://doi.org/10.23736/S 0026- 4784.18.04330-7
41. Agrawal S., Zaritsky J., Fornoni A., et al. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018; 14: 57–70. DOI: https://doi.org/10.1038/nrneph.2017.155
42. Theofilis P., Vordoni A., Koukoulaki M., Vlachopanos G., Kalaitzidis R.G. Dyslipidemia in chronic kidney disease: contemporary concepts and future therapeutic perspectives. Am J Nephrol. 2021; 52 (9): 693–701. DOI: https://doi.org/10.1159/000518456
43. Sniderman A.D., Couture P., Martin S.S., DeGraaf J., Lawler P.R., Cromwell W.C., et al. Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. J Lipid Res. 2018; 59 (7): 1266–75.
44. Karpov Y., Khomitskaya Y. PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia. Cardiovasc Diabetol. 2015; 14: 115. DOI: https://doi.org/10.1186/s12933-015-0268-2
45. Miller M., Stone N.J., Ballantyne C., Bittner V., Criqui M.H., Ginsberg H.N., et al.; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011; 123 (20): 2292–333.
46. Kim H., Hu E., Rebholz C. Ultra-processed food intake and mortality in the USA: results from the Third National Health and Nutrition Examination Survey (NHANES III, 1988–1994). Public Health Nutr. 2019; 22 (10): 1777–85. DOI: https://doi.org/10.1017/S1368980018003890
47. Boytsov S.A., Drapkina O.M., Shlyakhto E.V., Konradi A.O., Balanova Yu.A., Zhernakova Yu.V., et al. Epidemiology of Cardiovascular Diseases and their Risk Factors in Regions of Russian Federation (ESSE-RF) study. Ten years later. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2021; 20 (5): 143–52. DOI: https://doi.org/10.15829/1728-8800-2021-3007 (in Russian)
48. Castelli W.P. Epidemiology of triglycerides: a view from Framingham. Аm J Cardiol. 1992; 70 (19): Н3–9. DOI: https://doi.org/10.1016/0002-9149(92)91083-g
49. Toth P.P. Triglycerides and atherosclerosis: bringing the association into sharper focus. J Am Coll Cardiol. 2021; 77 (24): 3042–5. DOI: https://doi.org/10.1016/j.jacc.2021.04.058
50. Chait A., Ginsberg H.N., Vaisar T., et al. Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. 2020; 69 (4): 508–16. DOI: https://doi.org/10.2337/dbi19-0007

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)